Burning rock reports fourth quarter and full year 2023 financial results

Guangzhou, china, march 28, 2024 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”), a company focused on the application of next generation sequencing (ngs) technology in the field of precision oncology, today reported financial results for the three months and the year ended december 31, 2023. 2023 business overview and recent updates corporate updates completed profitability-driven organizational optimization, execution towards profitability well underway early detection   following the breakthrough device designation granted by the us food and drug administration (fda) for our overc™ multi-cancer detection blood test (mcdbt) in january 2023, our overc™ mcdbt also received the breakthrough device designation by china's national medical products administration (nmpa) in october 2023, making it the only test globally that has received breakthrough device designation from both the fda and the nmpa.
BNR Ratings Summary
BNR Quant Ranking